Outcomes according to age, DRI, and HCT-CI stratification
| . | OS . | P value . | PFS . | P value . | NRM . | P value . | Relapse . | P value . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 y | 3 y | 1 y | 3 y | 1 y | 3 y | 1 y | 3 y | |||||
| All patients | 84.4% (76.7%-92.9%) | 80.1% (71.5%-89.7%) | 82% (73.9%-91%) | 72.7% (63%-84%) | 7.7% (1.7%-13.6%) | 9.3% (2.6%-15.9%) | 10.3% (3.5%-17.1%) | 18.0% (8.8%-27.2%) | ||||
| Age, y | .35 | .35 | .42 | .65 | ||||||||
| ≤60 | 88.1% (77.9%-99.8%) | 85% (73.7%-98%) | 88.1% (77.9%-99.8%) | 75% (59.3%-94.9%) | 5.9% (0%-13.9%) | 5.9% (0%-13.9%) | 6.0% (0%-14.2%) | 19.1% (2.0%-36.2%) | ||||
| >60 | 81.5% (70.7%-93.9%) | 76.3% (64.5%-90.4%) | 77.3% (65.8%-99.7%) | 69.9% (57.4%-85.1%) | 9.1% (0.5%-17.7%) | 11.8% (1.9%-21.7%) | 13.6% (3.4%-23.9%) | 18.3% (6.7%-30.0%) | ||||
| HCT-CI | .39 | .25 | .94 | .17 | ||||||||
| <3 | 86.1% (76.4%-97.1%) | 83.2% (72.4%-95.5%) | 86.2% (76.6%-97.1%) | 78.4% (66.8%-92.1%) | 6.8% (0%-14.4%) | 9.8% (0.4%-19.2%) | 6.9% (0%-14.6%) | 11.7% (1.9%-21.5%) | ||||
| ≥3 | 82% (69.9%-96.1%) | 75.7% (62.3%-91.9%) | 76.5% (63.5%-92.1%) | 65.7% (50.7%-85%) | 8.8% (0%-18.5%) | 8.8% (0%-18.5%) | 14.7% (2.6%-26.8%) | 25.5% (9.4%-41.6%) | ||||
| DRI | <.0001 | .0001 | .13 | .0069 | ||||||||
| Low/intermediate | 93.4% (87.4%-99.9%) | 88.2% (80.3%-96.8%) | 91.8% (85.2%-99%) | 80.2% (70.1%-91.8%) | 4.9% (0%-10.4%) | 6.9% (0.3%-13.4%) | 3.3% (0%-7.8%) | 12.9% (3.5%-22.3%) | ||||
| High | 49.9% (30.3%-82.1%) | 49.9% (30.3%-82.1%) | 46.3% (27.6%-77.8%) | 46.3% (27.6%-77.8%) | 17.6% (0%-36.5%) | 17.6% (0%-36.5%) | 36% (11.7%-60.3%) | 36% (11.7%-60.3%) | ||||
| Disease | ||||||||||||
| AML | 77.9% (60.9%-99.7%) | 77.9% (60.9%-99.7%) | 73.3% (55.7%-96.4%) | 67.7% (49.4%-92.8%) | 5.3% (0%-15.6%) | 5.3% (0%-15.6%) | 21.4% (2.2%-40.7%) | 27.1% (6.0%-48.1%) | ||||
| MDS | 85.7% (72%-100%) | 80.4% (64.8%-99.7%) | 81% (65.8%-99.6%) | 81% (65.8%-99.6%) | 4.8% (0%-14.1%) | 4.8% (0%-14.1%) | 14.3% (0%-29.7%) | 14.3% (0%-29.7%) | ||||
| Myelofibrosis | 90.3% (80.5%-100%) | 86.7% (75.4%-99.8%) | 90.3% (80.5%-100%) | 74.9% (59.9%-93.6%) | 9.7% (0%-20.3%) | 13.3% (0.9%-25.8%) | 0% (0%-0%) | 11.8% (0%-25.2%) | ||||
| . | OS . | P value . | PFS . | P value . | NRM . | P value . | Relapse . | P value . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 y | 3 y | 1 y | 3 y | 1 y | 3 y | 1 y | 3 y | |||||
| All patients | 84.4% (76.7%-92.9%) | 80.1% (71.5%-89.7%) | 82% (73.9%-91%) | 72.7% (63%-84%) | 7.7% (1.7%-13.6%) | 9.3% (2.6%-15.9%) | 10.3% (3.5%-17.1%) | 18.0% (8.8%-27.2%) | ||||
| Age, y | .35 | .35 | .42 | .65 | ||||||||
| ≤60 | 88.1% (77.9%-99.8%) | 85% (73.7%-98%) | 88.1% (77.9%-99.8%) | 75% (59.3%-94.9%) | 5.9% (0%-13.9%) | 5.9% (0%-13.9%) | 6.0% (0%-14.2%) | 19.1% (2.0%-36.2%) | ||||
| >60 | 81.5% (70.7%-93.9%) | 76.3% (64.5%-90.4%) | 77.3% (65.8%-99.7%) | 69.9% (57.4%-85.1%) | 9.1% (0.5%-17.7%) | 11.8% (1.9%-21.7%) | 13.6% (3.4%-23.9%) | 18.3% (6.7%-30.0%) | ||||
| HCT-CI | .39 | .25 | .94 | .17 | ||||||||
| <3 | 86.1% (76.4%-97.1%) | 83.2% (72.4%-95.5%) | 86.2% (76.6%-97.1%) | 78.4% (66.8%-92.1%) | 6.8% (0%-14.4%) | 9.8% (0.4%-19.2%) | 6.9% (0%-14.6%) | 11.7% (1.9%-21.5%) | ||||
| ≥3 | 82% (69.9%-96.1%) | 75.7% (62.3%-91.9%) | 76.5% (63.5%-92.1%) | 65.7% (50.7%-85%) | 8.8% (0%-18.5%) | 8.8% (0%-18.5%) | 14.7% (2.6%-26.8%) | 25.5% (9.4%-41.6%) | ||||
| DRI | <.0001 | .0001 | .13 | .0069 | ||||||||
| Low/intermediate | 93.4% (87.4%-99.9%) | 88.2% (80.3%-96.8%) | 91.8% (85.2%-99%) | 80.2% (70.1%-91.8%) | 4.9% (0%-10.4%) | 6.9% (0.3%-13.4%) | 3.3% (0%-7.8%) | 12.9% (3.5%-22.3%) | ||||
| High | 49.9% (30.3%-82.1%) | 49.9% (30.3%-82.1%) | 46.3% (27.6%-77.8%) | 46.3% (27.6%-77.8%) | 17.6% (0%-36.5%) | 17.6% (0%-36.5%) | 36% (11.7%-60.3%) | 36% (11.7%-60.3%) | ||||
| Disease | ||||||||||||
| AML | 77.9% (60.9%-99.7%) | 77.9% (60.9%-99.7%) | 73.3% (55.7%-96.4%) | 67.7% (49.4%-92.8%) | 5.3% (0%-15.6%) | 5.3% (0%-15.6%) | 21.4% (2.2%-40.7%) | 27.1% (6.0%-48.1%) | ||||
| MDS | 85.7% (72%-100%) | 80.4% (64.8%-99.7%) | 81% (65.8%-99.6%) | 81% (65.8%-99.6%) | 4.8% (0%-14.1%) | 4.8% (0%-14.1%) | 14.3% (0%-29.7%) | 14.3% (0%-29.7%) | ||||
| Myelofibrosis | 90.3% (80.5%-100%) | 86.7% (75.4%-99.8%) | 90.3% (80.5%-100%) | 74.9% (59.9%-93.6%) | 9.7% (0%-20.3%) | 13.3% (0.9%-25.8%) | 0% (0%-0%) | 11.8% (0%-25.2%) | ||||
Median follow-up period for surviving patients: 36.4 months (range, 2.9-51.5).